Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

High-Dose Erythropoietin in Very Low Birth Weight Infants for the Potential Treatment of Prematurity-Related Cerebral Hemorrhagic-Ischemic Injury: A Phase II Safety/Tolerability Study

NCT00589953 is registered in ClinicalTrials.gov with Atlantic Health System as lead sponsor.

NCT NCT00589953
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00589953 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
High-Dose Erythropoietin in Very Low Birth Weight Infants for the Potential Treatment of Prematurity-Related Cerebral Hemorrhagic-Ischemic Injury: A Phase II Safety/Tolerability Study
Lead sponsor
Atlantic Health System
Phase
Phase 2
Overall status
Terminated
Start date
July 31, 2007
Completion date
September 30, 2010
Enrollment
22 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain injury, erythropoietin, infant, premature, intraventricular hemorrhage, neurodevelopmental outcomes, periventricular leukomalacia, randomized clinical trial